Announcements Trials

Browse Landscape

Phase

Phase 1 25 Phase 1/2 19 Phase 3 6 Phase 2 4 Phase 4 2 Phase 2/3 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Burkitt Lymphoma 1

Interventions

Cisplatin 29 Carboplatin 28 Gemcitabine 27 Paclitaxel 26 pembrolizumab 24 Capecitabine 16 Pemetrexed 15 Bevacizumab 15 Docetaxel 14 Oxaliplatin 13 Fluorouracil 12 Drug Therapy 12 Nivolumab 10 130-nm albumin-bound paclitaxel 9 Trastuzumab 8 anlotinib 7 Injections 7 Rituximab 6 venetoclax 5 atezolizumab 5 Temozolomide 5 Leucovorin 5 Ipilimumab 5 Lenalidomide 4 Irinotecan 4 Interferon alpha-2 4 Folfox protocol 4 Dexamethasone 4 Azacitidine 4 Albumin-Bound Paclitaxel 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × tocilizumab × Clear all

NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡